CRISPR Base Editing to Create Potential Charcot-Marie-Tooth Disease Models with High Editing Efficiency: Human Induced Pluripotent Stem Cell Harboring

CRISPR-Cas9 Charcot–Marie–Tooth (CMT) HEK293-T SH3TC2 disease cellular model hiPSCs

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
12 Jul 2024
Historique:
received: 28 05 2024
revised: 05 07 2024
accepted: 09 07 2024
medline: 27 7 2024
pubmed: 27 7 2024
entrez: 27 7 2024
Statut: epublish

Résumé

Human induced pluripotent stem cells (hiPSCs) represent a powerful tool to investigate neuropathological disorders in which the cells of interest are inaccessible, such as in the Charcot-Marie-Tooth disease (CMT), the most common inherited peripheral neuropathy. Developing appropriate cellular models becomes crucial in order to both study the disease's pathophysiology and test new therapeutic approaches. The generation of hiPS cellular models for disorders caused by a single nucleotide variation has been significantly improved following the development of CRISPR-based editing tools. In this study, we efficiently and quickly generated, by CRISPR editing, the two first hiPSCs cellular models carrying alterations involved in CMT4C, also called AR-CMTde-

Identifiants

pubmed: 39062123
pii: biomedicines12071550
doi: 10.3390/biomedicines12071550
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-20-CE17-0026
Organisme : Conseil Régional de Nouvelle-Aquitaine
ID : AAPR2021-2020-11765410

Auteurs

Camille Loret (C)

University of Limoges, NeurIT UR 20218, GEIST Institute, F-87000 Limoges, France.

Amandine Pauset (A)

University of Bordeaux, CRISP'edit, TBMCore UAR CNRS 3427, US Inserm 005, F-33000 Bordeaux, France.
University of Bordeaux, Modeling Transformation and Resistance in Leukemia, BRIC Inserm U1312, F-33000 Bordeaux, France.

Pierre-Antoine Faye (PA)

University of Limoges, NeurIT UR 20218, GEIST Institute, F-87000 Limoges, France.
CHU Limoges, Department of Biochemistry and Molecular Genetics, F-87000 Limoges, France.

Valérie Prouzet-Mauleon (V)

University of Bordeaux, CRISP'edit, TBMCore UAR CNRS 3427, US Inserm 005, F-33000 Bordeaux, France.
University of Bordeaux, Modeling Transformation and Resistance in Leukemia, BRIC Inserm U1312, F-33000 Bordeaux, France.

Ioanna Pyromali (I)

University of Limoges, NeurIT UR 20218, GEIST Institute, F-87000 Limoges, France.

Angélique Nizou (A)

University of Limoges, NeurIT UR 20218, GEIST Institute, F-87000 Limoges, France.

Federica Miressi (F)

University of Limoges, NeurIT UR 20218, GEIST Institute, F-87000 Limoges, France.

Franck Sturtz (F)

University of Limoges, NeurIT UR 20218, GEIST Institute, F-87000 Limoges, France.
CHU Limoges, Department of Biochemistry and Molecular Genetics, F-87000 Limoges, France.

Frédéric Favreau (F)

University of Limoges, NeurIT UR 20218, GEIST Institute, F-87000 Limoges, France.
CHU Limoges, Department of Biochemistry and Molecular Genetics, F-87000 Limoges, France.

Béatrice Turcq (B)

University of Bordeaux, CRISP'edit, TBMCore UAR CNRS 3427, US Inserm 005, F-33000 Bordeaux, France.
University of Bordeaux, Modeling Transformation and Resistance in Leukemia, BRIC Inserm U1312, F-33000 Bordeaux, France.

Anne-Sophie Lia (AS)

University of Limoges, NeurIT UR 20218, GEIST Institute, F-87000 Limoges, France.
CHU Limoges, Department of Biochemistry and Molecular Genetics, F-87000 Limoges, France.
CHU Limoges, Department of Bioinformatics, F-87000 Limoges, France.

Classifications MeSH